Families ruptured, some parents estranged from their children
In Brighton, England, a safety investigation has revealed that a GP clinic quietly became a gateway to irreversible medical treatment for 78 children — some as young as 11 — without the qualifications, oversight, or basic clinical safeguards such care demands. The WellBN clinic, born from genuine concern about long waiting lists, instead became a cautionary study in how good intentions, absent proper governance, can place the most vulnerable at serious risk. The findings arrive at a moment when the entire field of youth gender medicine is being reconsidered at the national level, making this local failure part of a much larger reckoning with how society navigates the intersection of identity, medicine, and the protection of children.
- Children as young as 11 received puberty blockers or cross-sex hormones — some without ever meeting a clinician in person — at a clinic that was never qualified or commissioned to provide such care.
- The investigation found that blood tests were routinely skipped, parental consent was sometimes bypassed, and over half the children had possible neuro-developmental conditions like autism or ADHD that went unaddressed amid the focus on gender treatment.
- Families have been torn apart by the fallout: one parent forged signatures were used to obtain hormones, another described facing an impossible choice between consent and suspicion, and one parent told the BBC the ordeal left him suicidal.
- NHS England has halted new prescriptions at the clinic, suspended one doctor from GP work, and referred multiple clinicians to medical regulators, while nationally pausing all new cross-sex hormone prescriptions for 16- and 17-year-olds pending public consultation.
- Most of the 78 children have now been referred to specialist NHS gender services, but the irreversible physical changes some may have already experienced mean the consequences of this failure cannot be fully undone.
An NHS safety investigation has concluded that a Brighton GP clinic prescribed gender medication to 78 children between 2023 and late 2025 without the safeguards, qualifications, or commissioning required for such sensitive care. The WellBN clinic had opened a transgender health hub in 2020 to help ease the severe backlog at England's specialist gender services — a well-intentioned response to a real crisis — but the investigation found its overall approach fell "far short of what could be considered safe or appropriate."
Among those treated were 44 children aged 16 and under who received puberty-blocking drugs, including 12 under the age of 13. A further 51 children in the same age group were given cross-sex hormones capable of producing irreversible changes. More than 20 children were prescribed medication without a single face-to-face appointment, and necessary blood tests were frequently skipped. Fifty-three of the 78 cases involved children with possible neuro-developmental conditions such as autism or ADHD — conditions that, investigators implied, were being overshadowed by the focus on gender treatment.
Three families shared their experiences with the BBC. One father discovered his 16-year-old son had forged a parent's signature to access oestrogen. Another described families being forced into an impossible position — consent or face suspicion for asking to slow down. A third parent, whose 13-year-old daughter had tried to order hormones online, accepted her testosterone prescription at 16 as the safer alternative; a year later, she stopped taking it, saying it hadn't made her happy, and is now living as a girl again. Rachel Cashman of parent group PSHE Brighton, which first raised concerns about the clinic in 2023, said the stress had ruptured families and left at least one parent suicidal.
NHS England has ordered the clinic to stop issuing new prescriptions to children, referred several clinicians to medical regulators, and suspended one doctor from NHS GP work. The investigation lands against a shifting national backdrop: the landmark 2024 Cass Review found the evidence base for medicating gender-questioning children "remarkably weak," leading to a ban on new puberty-blocker prescriptions outside trials. By March 2026, new cross-sex hormone prescriptions for 16- and 17-year-olds had been paused nationally pending public consultation. Most of the children affected in Brighton have now been referred to specialist services, though for some, the physical consequences of what happened at WellBN may already be permanent.
An NHS safety investigation into a Brighton GP practice has found that 78 children were prescribed gender medication between 2023 and late 2025 without the proper safeguards that such treatment demands. The WellBN clinic, which opened a transgender health hub in 2020 to address the severe waiting lists at England's three specialist gender services, operated without clinicians who were qualified or commissioned to deliver this kind of care. More than 20 of those children never had a face-to-face appointment before receiving medication. Some were as young as 11.
The investigation, conducted by five independent clinicians appointed by NHS Sussex and completed in 2025, examined cases after families began complaining about the clinic's treatment of minors. The report found that 44 children aged 16 and under received puberty-blocking drugs, including 12 children under 13. Another 51 children aged 16 and under, including four under 13, were prescribed cross-sex hormones—testosterone or oestrogen—which can produce irreversible physical changes such as a deeper voice or breast development. Necessary blood tests to monitor the children's physical health were often not carried out. The investigators concluded that the overall approach to care fell "far short of what could be considered safe or appropriate."
Dr Christopher Tibbs, regional medical director for NHS England, stated plainly: "Under no circumstances should this have happened." He noted that young people faced high risk of harm because clinicians provided specialist diagnosis and treatment they were neither qualified nor commissioned to deliver. NHS England has now instructed the clinic to stop offering new prescriptions to children. Several current and former clinicians have been referred to medical regulators, and one doctor has been suspended from NHS GP work pending further investigation. WellBN acknowledged the seriousness of the matters raised and said its priority remained providing compassionate, safe care.
The human toll extends beyond the medical risks. Three parents spoke to the BBC about their experiences. One father discovered his 16-year-old son had forged his mother's signature to access hormone treatment and was prescribed oestrogen without parental knowledge. Another parent learned his daughter had been given testosterone only weeks after she turned 16, describing families as facing an "impossible choice"—either consent to medical treatment or risk suspicion and ostracism for asking to slow the process. A third parent's 13-year-old daughter had attempted to order hormones online; when she was prescribed testosterone at 16, he welcomed it as preferable to that alternative, though he had reservations. A year later, she stopped taking the hormone, saying it "didn't make her happy," and is now living as a girl again.
Rachel Cashman, who co-founded PSHE Brighton, a group of parents, school governors, and social workers that began raising concerns about WellBN in 2023, described the stress as having "ruptured" families, leaving some parents estranged from their children. One parent told the BBC the situation had left him suicidal. Cashman noted that many of the children prescribed hormone treatments had also been diagnosed with autism, ADHD, or other neuro-developmental conditions—the report found 53 of the 78 cases reviewed had possible neuro-developmental issues—and the focus on gender medication risked overshadowing their wider health needs.
The investigation took place against a backdrop of shifting national policy. In April 2024, paediatrician Dr Hilary Cass released a landmark review finding the scientific evidence for medicating gender-questioning children was "remarkably weak" and calling for a fundamentally different service model. That led to a ban on new puberty-blocker prescriptions outside clinical trials. In 2024, NHS England tightened rules around cross-sex hormones, restricting them to those around 16 and older with "extreme caution" after specialist approval. In March 2026, new prescriptions were paused entirely for 16- and 17-year-olds pending public consultation. WellBN said it would work closely with NHS partners and regulators to address the report's recommendations. Most young patients registered at the clinic have now been referred to specialist NHS gender services for ongoing treatment.
Citações Notáveis
Young people were put at high risk of harm because clinicians provided specialist diagnosis, care and treatment that they were neither qualified, nor commissioned to deliver. Under no circumstances should this have happened.— Dr Christopher Tibbs, regional medical director for NHS England
The stress of the situation had ruptured families, leaving some parents estranged from their children. It's not just the medical damage, but the collateral damage for relationships and families that is far greater than people have ever really thought to examine.— Rachel Cashman, co-founder of PSHE Brighton
A Conversa do Hearth Outra perspectiva sobre a história
Why did a GP practice in Brighton start prescribing gender medication in the first place? That seems like a significant departure from what a general practice normally does.
The clinic opened its transgender health hub in 2020 because patients were facing years-long waits to see one of England's three specialist gender services. There was a genuine gap in care, and the staff had real compassion for distressed young people. But compassion isn't the same as competence or proper authorization.
The report says 78 children were prescribed these medications. How many of them actually experienced harm that we can measure?
That's the difficult part. The report says the overall risk was potentially high, but actual harm is hard to quantify because record-keeping was so poor. We know some children experienced irreversible physical changes. We know one stopped treatment a year later and regretted it. But we don't have a full accounting.
What strikes me about the parent accounts is how trapped they felt. One said families faced an "impossible choice." Can you explain that?
Parents were essentially told: consent to treatment here, or your child will pursue it online or through other means. Some children were forging signatures. One tried to order hormones over the internet. The clinic positioned itself as the safer option, even when parents had doubts.
The report mentions that 53 of the 78 children had possible neuro-developmental issues like autism or ADHD. Why does that matter?
Because those conditions can affect how a young person processes identity questions and makes decisions. If a clinician isn't trained to recognize that complexity, they might focus narrowly on gender medication and miss the bigger picture of what the child actually needs.
What happens to these children now?
Most have been referred to the specialist NHS gender services—the ones with the long waits that created this problem in the first place. The clinic can't prescribe to children anymore. And nationally, new prescriptions for 16- and 17-year-olds are paused while the government consults on what the rules should be.